Lung Disease News and Research

RSS

Now is the best time to get immunized against influenza, says UAB expert

It is that time of year again to consider the protection offered by a flu shot. One University of Alabama at Birmingham internal medicine expert says with a vaccine already available, it is best to get immunized against influenza now.

20 Sep 2013

IPF World Week underlines the need for integrated approach towards idiopathic pulmonary fibrosis

This year's IPF World Week (September 21-29) sees healthcare professionals, patient advocacy groups, people living with idiopathic pulmonary fibrosis (IPF), who have an estimated median survival time of two to five years, and their families calling for an integrated approach to further strengthen the national and international network of people working to support patients with this fatal orphan lung disease.

20 Sep 2013

GERD prevalence raised even in mild–moderate COPD, bronchiectasis

Researchers from Australia have found that the rate of gastroesophageal reflux disease is twice as high in patients with chronic obstructive pulmonary disease or bronchiectasis as in people without lung disease.

18 Sep 2013

Gout: An Interview with Dr. Lawrence Edwards, Chairman and CEO of GUAES

Gout is the most common form of inflammatory arthritis that affects adults. It's a disease caused by the presence of uric acid crystals in and around the joints. It's a disease that's becoming more and more common. It probably has doubled in its prevalence worldwide over the past twenty to thirty years.

18 Sep 2013

Dual-pronged approach to diabetes and COPD needed

Researchers from the USA have found that patients with diabetes and a history of smoking have significantly impaired lung function, even in the absence of overt chronic obstructive pulmonary disease.

17 Sep 2013

Improved lung function in patients with moderate asthma severity observed with investigational Tiotropium

Boehringer Ingelheim will present a pooled analysis of new data from the Phase 3 UniTinA-asthma® program at the European Respiratory Society (ERS) Annual Congress 2013 in Barcelona. The data from the individual MezzoTinA-asthma® Phase 3 studies (NCT01340209 and NCT00565266), from which the pooled data are derived, show the addition of tiotropium delivered via the Respimat® inhaler to medium-dose maintenance inhaled corticosteroid (ICS) therapy (defined as 400-800 µg budesonide/day or equivalent) improved lung function and provided sustained bronchodilation over 24 hours in patients with moderate asthma and airflow limitation. Tiotropium is being investigated to determine the medicine’s efficacy in treating asthma patients and is not currently approved for this indication.

11 Sep 2013

Hospira announces EC approval of Inflectra, Europe's first biosimilar mAb therapy

Hospira, the world's leading provider of injectable drugs and infusion technologies, today announced the European Commission (EC) approval of Inflectra™ (infliximab), Europe's first biosimilar monoclonal antibody (mAb) therapy. Inflectra has been approved for the treatment of inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis, Crohn's disease (CD), ulcerative colitis (UC), psoriatic arthritis (PsA) and psoriasis.

10 Sep 2013

Patients with COPD show improvements in lung function with olodaterol

Data from the olodaterol Phase 3 clinical program, presented for the first time at the European Respiratory Society (ERS) Annual Congress 2013 in Barcelona, showed the addition of olodaterol 5 and 10 µg delivered once daily via the Respimat® inhaler provided improvements in lung function in patients with moderate to very severe chronic obstructive pulmonary disease (COPD).

10 Sep 2013

Drug can be delivered safely to people with COPD in both "mist" and "dry powder" inhalers, say experts

An international study led by a Johns Hopkins pulmonary expert finds that the drug tiotropium (marketed as the Spiriva brand), can be delivered safely and effectively to people with chronic obstructive pulmonary disease (COPD) in both "mist" and traditional "dry powder" inhalers.

10 Sep 2013

Once-daily COPD portfolio data from Novartis presented at European Respiratory Society (ERS) Annual Congress

Novartis announced new analyses of data for once-daily Ultibro® Breezhaler® (investigational QVA149 - indacaterol 85 mcg/glycopyrronium 43 mcg delivered dose, equivalent to 110 mcg/50 mcg metered dose per capsule), which showed significant improvements in lung function, shortness of breath and health-related quality of life for chronic obstructive pulmonary disease (COPD) patients versus all comparators1,2. These data were part of 39 respiratory abstracts presented at the European Respiratory Society (ERS) Annual Congress in Barcelona, Spain.

9 Sep 2013

Indicators of poor preoperative health predict risk of major medical complications

For older adults undergoing surgery for spinal stenosis, some simple indicators of poor preoperative health predict a high risk of major medical complications, reports a study in the September 1 issue of Spine. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

4 Sep 2013

BP and headache drug effectively speeds up treatment of TB

Infectious disease experts at Johns Hopkins have found, in studies in mice, that a drug better known as a treatment for high blood pressure and headaches effectively speeds up treatment of TB when added to the standard, daily antibiotic regimen. Test animals were cured in four months instead of the usual six.

30 Aug 2013

Researchers discover additional cystic fibrosis-causing mutations

Of the over 1,900 errors already reported in the gene responsible for cystic fibrosis, it is unclear how many of them actually contribute to the inherited disease. Now a team of researchers reports significant headway in figuring out which mutations are benign and which are deleterious. In so doing, they have increased the number of known CF-causing mutations from 22 to 127, accounting for 95 percent of the variations found in patients with CF.

26 Aug 2013

BESTCILIA project aims to improve screening, treatment of Primary Ciliary Dyskinesia

Primary Ciliary Dyskinesia is mainly a lung disease: a rare, genetically heterogeneous disorder resulting from dysfunction of small hair-like organelles (cilia) that clean the upper and lower airways. It can also affect multiple organs beside the respiratory system, and may cause serious impairment and lower quality of life. Its prevalence is estimated to be about 1 in 16,000.

26 Aug 2013

Researchers request all countries to record smoking on death registries

Researchers today [Friday 23 August] call for official death registries in all countries to record whether the dead person was a smoker, in a research Article published in The Lancet.

23 Aug 2013

Study confirms exposure to arsenic in drinking water can impair lung function

A new study confirms that exposure to low to moderate amounts of arsenic in drinking water can impair lung function. Doses of about 120 parts per billion of arsenic in well water-about 12 times the dose generally considered safe-produced lung damage comparable to decades of smoking tobacco. Smoking, especially by males, made arsenic-related damage even worse.

23 Aug 2013

Twice-daily KALYDECO improves lung function in people with cystic fibrosis

Vertex Pharmaceuticals (Australia) Pty Ltd., announces the presentation of data from KALYDECO (ivacaftor) studies at the 10th Australasian Cystic Fibrosis Conference in Auckland, New Zealand, August 17 – 20, 2013, which further demonstrate the benefits of the medicine in people with cystic fibrosis ages 6 and older who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator gene.

21 Aug 2013

Investigators link acute viral infections to development of COPD

Investigators at Washington University School of Medicine in St. Louis have described another link in the chain of events that connect acute viral infections to the development of chronic obstructive pulmonary disease (COPD).

16 Aug 2013

Chronic exposure biomass fuel smoke can cause cardiovascular problems

Rural households in developing countries often rely on burning biomass, such as wood, animal dung and waste from agricultural crops, to cook and heat their homes. The practice is long known to cause lung disease, but a new study from Washington University School of Medicine in St. Louis and Johns Hopkins University School of Medicine links the resulting smoke to cardiovascular problems, including an increase in artery-clogging plaques, artery thickness and higher blood pressure.

8 Aug 2013

Findings may allow lower doses of chemotherapy, limit toxic side effects

In research recently published in Nature Structural & Molecular Biology, Alessandro Vindigni, Ph.D., associate professor of biochemistry and molecular biology at Saint Louis University, discovered how cancer cells respond to the damage caused by an important class of anti-cancer drugs, topoisomerase I inhibitors.

7 Aug 2013

Lung Disease News and Research

Now is the best time to get immunized against influenza, says UAB expert

IPF World Week underlines the need for integrated approach towards idiopathic pulmonary fibrosis

GERD prevalence raised even in mild–moderate COPD, bronchiectasis

Gout: An Interview with Dr. Lawrence Edwards, Chairman and CEO of GUAES

Dual-pronged approach to diabetes and COPD needed

Improved lung function in patients with moderate asthma severity observed with investigational Tiotropium

Hospira announces EC approval of Inflectra, Europe's first biosimilar mAb therapy

Patients with COPD show improvements in lung function with olodaterol

Drug can be delivered safely to people with COPD in both "mist" and "dry powder" inhalers, say experts

Once-daily COPD portfolio data from Novartis presented at European Respiratory Society (ERS) Annual Congress

Indicators of poor preoperative health predict risk of major medical complications

BP and headache drug effectively speeds up treatment of TB

Researchers discover additional cystic fibrosis-causing mutations

BESTCILIA project aims to improve screening, treatment of Primary Ciliary Dyskinesia

Researchers request all countries to record smoking on death registries

Study confirms exposure to arsenic in drinking water can impair lung function

Twice-daily KALYDECO improves lung function in people with cystic fibrosis

Investigators link acute viral infections to development of COPD

Chronic exposure biomass fuel smoke can cause cardiovascular problems

Findings may allow lower doses of chemotherapy, limit toxic side effects

The ultimate guide to lung research tools and protocols eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News